Compare Marsh & McLennan Companies, Inc. (MRSH) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marsh & McLennan Companies, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 5× Zimmer Biomet Holdings Inc's market cap, and Marsh & McLennan Companies, Inc. pays the higher dividend (2.24%). Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MRSH | ZBH | |
|---|---|---|
Market Cap | $84.31B | $16.95B |
Volume | 3,948,947 | 2,505,240 |
Sector | Financials | Health |
52-Week High | $207.02 | $103.98 |
52-Week Low | $157.32 | $79.58 |
Typical Hold Time | 109 Days | 89 Days |
Enterprise Value | $104.99B | $24.02B |
Dividend Yield | 2.24% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marsh (MRSH) trades at $175.76, up 1.21% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by robust fundamentals, including a 25.72% ROE and 14.24% net income margin, alongside the recent acquisition of Accel Holdings announced on October 2, 2026. Revenue has grown steadily, reaching $27.0B in 2025, though profit margins have slightly softened.
The outlook remains positive with a consensus price target of $202.71, implying 15% upside, but risks include high valuation multiples and competitive pressures. Analysts are predominantly neutral, with 65% hold ratings, suggesting cautious optimism amid solid operational performance.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
